Russo A, et al. - Researchers sought to assess if indomethacin eye drops and intravitreal ranibizumab (IVR) injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularization (CNV). They conducted 12 months follow up. In patients with naive CNV lesions, combination therapy with indomethacin eye drops and IVR provided superior anatomical and visual outcomes vs IVR monotherapy. Furthermore, the frequency of IVR injections could be reduced by the topical indomethacin, which was very beneficial considering the chronic and expensive nature of IVR therapy. The mean central retinal thickness (CRT) in the ranibizumab monotherapy (RM) group at 12 months was significantly higher compared to that in the ranibizumab plus indomethacin (RI) group.